Multiple sclerosis: role of meningeal lymphoid aggregates in progression independent of relapse activity
Trends in Immunology

Abata Therapeutics Appoints David Kaufman, M.D., Ph.D., to its Board of Directors

Abata Therapeutics Announces First Development Candidate, ABA-101, a Novel Treg Cell Therapy for the Treatment of Progressive Multiple Sclerosis

Abata Therapeutics Appoints Ellen Cahir-McFarland, Ph.D., as Chief Scientific Officer

Abata Therapeutics to Participate in Guggenheim’s 4th Annual Immunology and Neurology Day Â
